Ask AI
ProCE Banner Activity

Optimizing CAR T-Cell Therapy in Multiple Myeloma: Practical Insights on Patient Selection, Bridging, and Sequencing

Clinical Thought

CAR T-cell therapy has transformed the treatment landscape for patients with relapsed/refractory multiple myeloma. As these therapies move earlier in the treatment course, healthcare professionals have an opportunity to improve outcomes for more patients. In this ClinicalThought, expert faculty share practical insights from clinical trials and real-world experience, including strategies for optimizing outcomes in older patients and those with high-risk disease or comorbidities. They also explore how emerging bispecific antibody combinations may influence treatment sequencing and highlight the importance of collaboration between community and academic centers to support patients throughout the CAR T-cell therapy journey.

Released: November 20, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Johnson & Johnson and Legend Biotech USA Inc.

Johnson & Johnson

Legend Biotech USA Inc.

Target Audience

This activity is intended for hematologists, oncologists, advanced practice providers, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply patient selection and eligibility criteria for BCMA-directed CAR-T therapy in MM, including evidence-informed considerations for high-risk disease, older or frail patients, and those with clinically relevant comorbidities 

  • Implement bridging and sequencing strategies across BCMA CAR-T and T-cell–redirecting therapies (including bispecific antibodies), using emerging clinical trial and real-world evidence to optimize timing, target selection, and downstream options

  • Integrate new and evolving BCMA CAR-T data, including earlier-line use, durability of response, and real-world experience, into practical, patient-specific treatment decisions

  • Recognize, differentiate, and manage CAR-T–associated adverse events, with emphasis on CRS and ICANS, as well as late/atypical neurotoxicities reported with BCMA-directed constructs (eg, Parkinsonian features and cranial nerve palsies), to support timely triage and safe care delivery 

Financial Disclosures

Primary Author

Doris K. Hansen, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Janssen, Karyopharm, Kite/Gilead, Legend, Pfizer; researcher: Adaptive Biotechnologies, Bristol Myers Squibb, Janssen, Karyopharm, Kite/Gilead.

Surbhi Sidana, MD: researcher: Bristol Myers Squibb, Janssen, Kelonia, Kite, Novartis; consultant/advisor/speaker: AbbVie, Arcellx, BiolineRx, Bristol Myers Squibb, Cell Centric, Genentech, Janssen, Kite, Legend, Lilly, Pfizer, Regeneron, Sanofi, Takeda.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for drafting educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.